ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

12,566Medicare Part D Prescriptions Filled, Including Refills

Rank: 27 out of 1942

$620K Total Retail Price of All Prescriptions

Rank: 29 out of 1942

389 Patients Receiving at Least One Drug in Part D
97%Patients 65 Years and Older
49% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Minnesota
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 389 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

4% of this provider’s 389 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

0% of this provider’s 12,365 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 20%.

Prescription Price

$49 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

32 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Minnesota
FUROSEMIDE 615 615 1 5
LISINOPRIL 569 563 2 2
LEVOTHYROXINE SODIUM 560 556 3 3
CITALOPRAM HBR 520 513 4 15
OMEPRAZOLE 479 477 5 4
DONEPEZIL HCL 398 398 6 30
NAMENDA 361 356 7 51
METOPROLOL TARTRATE 314 306 8 9
SERTRALINE HCL 311 311 9 20
TRAZODONE HCL 305 296 10 24
MIRTAZAPINE 277 275 11 38
SIMVASTATIN 277 277 11 1
AMLODIPINE BESYLATE 277 277 11 6
DIVALPROEX SODIUM 224 220 14 91
GABAPENTIN 222 219 15 16
ATENOLOL 219 219 16 7
WARFARIN SODIUM 218 218 17 11
QUETIAPINE FUMARATE 191 191 18 61
POLYETHYLENE GLYCOL 3350 149 149 19 28
RISPERIDONE 143 143 20 68
TRAMADOL HCL 135 135 21 19
CARBIDOPA-LEVODOPA 133 133 22 64
METOPROLOL SUCCINATE 131 131 23 13
JANTOVEN 131 131 23 33
POTASSIUM CHLORIDE 125 125 25 17
PREDNISONE 121 121 26 27
HYDROCHLOROTHIAZIDE 119 112 27 8
NYSTATIN 101 101 28 140
LIDODERM 99 97 29 98
METFORMIN HCL 96 96 30 10
IPRATROPIUM-ALBUTEROL 85 85 31 134
CARVEDILOL 83 83 32 39
LANTUS 81 75 33 49
LEVETIRACETAM 81 77 33 112
PANTOPRAZOLE SODIUM 76 76 35 48
TAMIFLU 74 74 36 160
ISOSORBIDE MONONITRATE ER 72 72 37 42
OLANZAPINE 71 70 38 94
NYSTOP 71 71 38 128
VITAMIN D2 71 71 38 156
DIGOXIN 71 71 38 40
CLOPIDOGREL 70 70 42 55
KLOR-CON M20 69 69 43 97
MAPAP 66 66 44 104
KLOR-CON M10 65 65 45 148
RANITIDINE HCL 59 51 46 31
GLIPIZIDE 56 56 47 63
NOVOLOG 55 55 48 103
ESCITALOPRAM OXALATE 55 55 48 127
SEROQUEL 55 55 48 146
CEPHALEXIN 52 52 51 119
HALOPERIDOL 51 51 52 180
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 25, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.